Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Hernia ; 21(5): 697-703, 2017 10.
Article in English | MEDLINE | ID: mdl-28488073

ABSTRACT

PURPOSE: Robotic LaparoEndoscopic Single-Site Surgery Cholecystectomy has been performed for 5 years using a dedicated platform (da Vinci® Single-Site®) with the da Vinci® Surgical System (Intuitive Surgical Inc., Sunnyvale, CA, USA). While short-term feasibility has been described, long-term assessment of this method is currently outstanding. The aim of this study was to assess long-term parietal complications of this technique. METHODS: In this retrospective study, patients operated between 2011 and 2013 were evaluated. Parietal incision was assessed with ultrasonography and patients screened for residual pain from scar tissue. Demographic and perioperative data were also collected. RESULTS: We evaluated 48 patients [38 female, 79.2%; median age 49 years (range: 24-81 years)]; mean BMI 25.9 kg/m2 [±SD 4.1 kg/m2]. After a median follow-up of 39 months (range: 25-46 months), six incisional hernias (two patients had a positive echography but a negative clinical examination) were found (12.5%, 95% CI 7.5-30.2), and two patients had a surgical repair. The overall rate of incisional hernia was 16.7% (95% CI 7.5-30.2). Residual pain was observed in 5 of 48 patients. CONCLUSION: This preliminary study suggests that a clinically significant rate of incisional hernias can occur after R-LESS-C. Larger studies comparing R-LESS-C to alternative methods with long-term follow-up are necessary.


Subject(s)
Cholecystectomy/adverse effects , Incisional Hernia/diagnostic imaging , Robotic Surgical Procedures/adverse effects , Adult , Aged , Aged, 80 and over , Female , Humans , Incisional Hernia/etiology , Male , Middle Aged , Pilot Projects , Retrospective Studies , Ultrasonography , Young Adult
3.
Rev Med Suisse ; 10(435): 1350-5, 2014 Jun 18.
Article in French | MEDLINE | ID: mdl-25051598

ABSTRACT

Regenerative medicine aims to replace a body function or specific cell loss. It includes therapies at the forefront of modem medicine, issuing from translational biomedical research. Transplantation of organs and cells has revolutionized the management of patients for whom medical treatment is a failure. Unfortunately, organ shortage is limiting treatment possibility. As an example, among the 15,000 patients with type I diabetes in Switzerland, only approximately 30 can receive a pancreas or an islet transplant per year. Second example, 500 patients die each year in Switzerland from alcoholic cirrhosis because no treatment is available. Transplantation of islet cells, hepatocytes, mesenchymal stem cells or dopaminergic neurons represents hope fora therapy available for large populations of patients.


Subject(s)
Cell Transplantation/methods , Organ Transplantation/statistics & numerical data , Regenerative Medicine/methods , Cell Transplantation/trends , Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 1/therapy , Humans , Islets of Langerhans Transplantation/methods , Liver Cirrhosis, Alcoholic/epidemiology , Liver Cirrhosis, Alcoholic/therapy , Regenerative Medicine/trends , Switzerland/epidemiology , Translational Research, Biomedical/methods
5.
Cell Transplant ; 15(2): 89-104, 2006.
Article in English | MEDLINE | ID: mdl-16719044

ABSTRACT

Islet allotransplantation has been shown to have potential as a treatment for type 1 diabetic patients. Xenotransplantation, using the pig as a donor, offers the possibility of an unlimited number of islets. This comprehensive review focuses on experience obtained in pig-to-nonhuman primate models, particularly with regard to the different types of islets (fetal, neonatal, adult) and isolation procedures used, and the methods to determine islet viability. The advantages and disadvantages of the methods to induce diabetes (pancreatectomy, streptozotocin) are discussed. Experience in pig-to-nonhuman primate islet transplantation studies is reviewed, including discussion of the possible mechanisms of rejection and the immunosuppressive regimens used. The research carried out to date has led to workable animal models to study islet xenotransplantation, but several questions regarding methodology remain unanswered, and details of these practicalities require to be adequately addressed. The encouraging porcine islet survival reported recently provides an indicator for future immunosuppressive regimens.


Subject(s)
Islets of Langerhans Transplantation/methods , Primates/immunology , Swine/immunology , Transplantation, Heterologous/methods , Aging/immunology , Aging/pathology , Animals , Animals, Newborn , Cell Survival , Diabetes Mellitus, Type 1/chemically induced , Diabetes Mellitus, Type 1/pathology , Diabetes Mellitus, Type 1/therapy , Graft Rejection/immunology , Immunosuppression Therapy , Islets of Langerhans/immunology , Islets of Langerhans/pathology , Islets of Langerhans Transplantation/immunology , Islets of Langerhans Transplantation/pathology , Pancreatectomy , Streptozocin , Temperature , Transplantation, Heterologous/immunology , Transplantation, Heterologous/pathology
6.
Eur J Surg Oncol ; 32(3): 310-4, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16414236

ABSTRACT

AIM: To analyze GIST outcome after primary resection and to determine if a new grading system could adequately predict there prognosis. METHODS: A retrospective review (1993-2002) identified 80 patients who underwent primary surgical resection for, c-KIT positive, GIST. Follow-up was complete for all patients (median follow-up 42, range 1-132, months). GIST were classified as low or high grade according to the following parameters: size, mitotic rate, mitotic index (MiB1), presence of necrosis, invasion of adjacent structure and presence of metastasis. RESULTS: GIST originated from the stomach (46), small bowel (30), colon and rectum two and mesentery two. At surgery, 94% of cases presented with localized disease and 6% blood born metastasis with or without lymph node invasion. Resections were complete (R0) in 72 cases. R0 resection correlated with prognosis (p<0.01). Sixty GIST were classified as low grade (median follow-up 60 months) and 20 as high grade (median follow-up 27 months). Five-year actuarial survival of patients with low or high grade GIST were of 95 and 21%, respectively, (p<0.001). CONCLUSION: Prognosis of GIST after surgical treatment is influenced by completeness of primary resection and tumour malignant potential. Low grade GIST have an excellent prognosis after surgery alone, while high grade GIST have a high rate of recurrence after primary resection. Adjuvant treatment should be advocated for patient with either high grade GIST or after incomplete primary resection. The presented grading system can reliably predict GIST outcome after primary surgical treatment. Complete surgical resection offers good chance of cure for low grade GIST, while for high grade GIST surgery alone is not sufficient. The presented grading system could be used to identify patients who may benefit of adjuvant treatment with imatinib mesylate after GIST resection.


Subject(s)
Digestive System Surgical Procedures/standards , Gastrointestinal Stromal Tumors/surgery , Medical Audit , Adult , Aged , Aged, 80 and over , Disease Progression , Female , Follow-Up Studies , Gastrointestinal Stromal Tumors/mortality , Gastrointestinal Stromal Tumors/pathology , Humans , Male , Middle Aged , Neoplasm Staging , Prognosis , Retrospective Studies , Survival Rate/trends
7.
Ann Chir ; 130(6-7): 374-83, 2005.
Article in French | MEDLINE | ID: mdl-15992762

ABSTRACT

Diabetes is one of the most common chronic diseases in our society. While insulin treatment for diabetes type I could delay and reduce the incidence of diabetic complications, it is associated with an increased risk of severe hypoglycemia. To restore physiologic insulin metabolism, transplantation of insulin producing cells (pancreatic Beta cells) represent the sole available therapy. It could be done either through pancreas or islet of Langerhans transplantation. In this paper, we review actual knowledge regarding these two types of transplantations.


Subject(s)
Diabetes Mellitus, Type 1/therapy , Islets of Langerhans Transplantation , Pancreas Transplantation , Humans
8.
Transplant Proc ; 37(1): 460-2, 2005.
Article in English | MEDLINE | ID: mdl-15808676

ABSTRACT

BACKGROUND: Costimulatory blockade has been shown to allow long-term survival of xenogeneic islets. The aim of the present study was to evaluate the role of recipient CD40 and CD154 in the rejection process of concordant and discordant islet xenotransplantation (Tx). METHODS: Diabetic C57BL/6 mice, CD40- or CD154 knockout (KO) mice were transplanted with either concordant rat or discordant human islets. EXPERIMENTAL DESIGN: group 1, control (ie, C57BL/6 mice received islet Tx without therapy); group 2, C57BL/6 mice received islet Tx with anti-CD154 monoclonal Ab (mAb) therapy; group 3, CD40 KO mice; and group 4, CD154 KO mice were used as recipients without therapy. Mouse anti-rat mixed lymphocyte reactions (MLR) were performed using mouse splenocytes obtained from animals transplanted with rat islets in groups 1 to 4. RESULTS: In group 2, short-term anti-CD154 mAb therapy significantly prolonged rat-to-mouse and human-to-mouse xenograft survival, compared to controls. In CD40-KO and CD154-KO recipients, survival of concordant or discordant islets was not prolonged significantly compared to control groups. Mouse anti-donor rat cellular responses were reduced approximately 50% in group 2 but remained unmodified in groups 3 and 4, when compared to group 1. CONCLUSIONS: Improved graft survival and reduced MLR responses against donor cells in vitro among the anti-CD154 mAb-treated mice could be explained by specific targeting of activated T cells with subsequent inactivation by anergy and/or elimination by apoptosis, or complement- or cellular-mediated mechanisms. Rejection of xenografts and strong MLR responses against donor cells in vitro in CD40 or CD154 KO animals is possible through efficient activation of alternate pathways of costimulation.


Subject(s)
CD40 Antigens/physiology , CD40 Ligand/physiology , Graft Rejection/pathology , Islets of Langerhans Transplantation/pathology , Animals , CD40 Antigens/genetics , CD40 Ligand/genetics , Gene Deletion , Humans , Lymphocyte Culture Test, Mixed , Mice , Mice, Inbred C57BL , Mice, Knockout , Rats , Transplantation, Heterologous/pathology
9.
Transplant Proc ; 37(1): 463-5, 2005.
Article in English | MEDLINE | ID: mdl-15808677

ABSTRACT

BACKGROUND: Cellular immunity plays a major role in rejection of xenografted islets. Depending on the phylogenetical disparity, direct or indirect antigen presentation is predominant. The aim of this study was to analyze in vitro the predominance of direct or indirect presentation, and in vivo the effect of macrophage depletion on concordant and discordant islet xenograft survival. MATERIALS AND METHODS: In vitro, we performed mouse antirat and mouse antihuman mixed lymphocyte reactions (MLR) after depletion of responder or stimulator antigen-presenting cells. In vivo, streptozotocin-induced diabetic C57BL/6 mice were treated by gadolinium chloride to deplete macrophages and rat or human islets were transplanted under the kidney capsule. Islet function was followed by glycemia and xenografts were analyzed at regular intervals for histology. RESULTS: Mouse antirat MLR showed a predominant direct antigen presentation pathway, whereas in mouse antihuman MLR, direct and indirect pathways were similarly involved. Survival of rat islets was not modified by GdCl therapy. In contrast, survival of human islets was significantly prolonged in GdCl-treated mice. Macrophage infiltration was decreased in concordant and discordant GdCl-treated xenografts at day 4, compared to controls. At day 15, macrophage infiltration was similar in all groups. DISCUSSION: Our results indicate that direct antigen presentation is dominant in rejection of concordant islet xenografts and cannot be influenced by host macrophage depletion. Both direct and indirect antigen presentation are involved in rejection of discordant xenogeneic islets. Macrophage depletion or inhibition should be considered as therapeutic tool for discordant islet xenotransplantation.


Subject(s)
Antigen Presentation/immunology , Graft Rejection/immunology , Graft Survival/immunology , Islets of Langerhans Transplantation/immunology , Transplantation, Heterologous/immunology , Animals , Humans , Lymphocyte Culture Test, Mixed , Male , Mice , Mice, Inbred C57BL , Phylogeny , Rats , Rats, Sprague-Dawley , Time Factors
10.
Transplant Proc ; 37(1): 527-9, 2005.
Article in English | MEDLINE | ID: mdl-15808699

ABSTRACT

BACKGROUND: The aim of this study was to evaluate the in vitro and in vivo function of hepatocytes after immortalization, cryopreservation, encapsulation, and xenotransplantation into mice with fulminant liver failure (FLF). METHODS: Rat and human hepatocytes were isolated by collagenase digestion. Human hepatocytes were immortalized using lentiviral vectors. Rat and immortalized human hepatocytes (IHH) were encapsulated in 400 microm of alginate-poly-L-lysine (PLL; Sigma, Buchs, Switzerland)-alginate membranes and cryopreserved using a computerized device. In vitro, encapsulated hepatocytes (cryopreserved or noncryopreserved) were cultured; albumin secretion was measured by enzyme-linked immunosorbent assay. Microencapsulated (cryopreserved or noncryopreserved) hepatocytes were transplanted intraperitoneally to mice with FLF: group 1 (n = 10) transplantation of empty capsules; group 2 (n = 12) transplantation of free primary rat hepatocytes; group 3 (n = 12) transplantation of cryopreserved encapsulated rat hepatocytes; group 4 (n = 10) transplantation of encapsulated rat hepatocytes; group 5 (n = 9) transplantation of cryopreserved encapsulated IHH; group 6 (n = 10) transplantation of encapsulated IHH. RESULTS: Compared with free primary hepatocytes, cryopreserved or noncryopreserved encapsulated rodent hepatocytes showed similar levels of continuous in vitro albumin secretion over 1 week. Cryopreserved or noncryopreserved encapsulated IHH showed minimal albumin secretion compared with free primary human hepatocytes. Fulminant liver failure, produced by a combination of acetaminophen and 30% hepatectomy, resulted in a 20% to 30% host survival. In groups 1 and 2, survival was unmodified, compared with untreated mice. For groups 3 and 4, transplantation of cryopreserved or noncryopreserved encapsulated rat hepatocytes significantly increased survival rates to 66% and 80%, respectively (P < .01). For groups 5 and 6, transplantation of cryopreserved or noncryopreserved encapsulated IHH improved host survival to 50% and 55%, respectively (P < .05). CONCLUSIONS: Primary rodent hepatocytes maintained synthetic functions after encapsulation and cryopreservation. Immortalized human hepatocytes showed minimal albumin secretion in the absence of encapsulation and cryopreservation, suggesting that hepatocytes lose some specific functions after immortalization. After induction of FLF in mice, intraperitoneal transplantation of encapsulated (primary or immortalized, cryopreserved or noncryopreserved) xenogeneic hepatocytes significantly improved survival. These results indicate that naive and genetically modified hepatocytes can be successfully encapsulated, stored by cryopreservation, and transplanted into xenogeneic recipients with FLF to sustain liver metabolic functions.


Subject(s)
Hepatocytes/transplantation , Liver Failure, Acute/therapy , Transplantation, Heterologous/methods , Animals , Capsules , Cryopreservation , Graft Survival , Humans , Mice , Rats , Rats, Sprague-Dawley
11.
Transplant Proc ; 37(2): 1326-7, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15848711

ABSTRACT

AIM: Islet transplantation is gaining recognition as a therapeutic option for selected diabetic patients. The immunosuppressive regimen based on sirolimus/low-dose tacrolimus is considered a major breakthrough that allowed considerable improvement in graft survival. A high incidence of side effects associated with such a regimen has been reported in the literature, but this immunosuppressive protocol is generally considered safe or even protective to the kidney. Herein, we analyze the impact of the sirolimus/low-dose tacrolimus-based protocol on kidney function. PATIENTS AND METHODS: Five islet-after-kidney and 5 islet-transplant-alone patients were enrolled and followed up. Renal function was assessed by the periodic measurement of serum creatinine and by the presence of albuminuria. Metabolic control markers and graft function were followed, as well as immunosuppressive whole blood trough levels. RESULTS: Kidney function significantly decreased in 6 of 10 patients. Neither metabolic markers nor immunosuppressive drugs levels were significantly associated with the decreased kidney function. CONCLUSION: Although a specific etiology was not identified, subsets of patients presented a higher risk for decrease of kidney function. The presence of low creatinine clearance, albuminuria, and long-established kidney graft were associated with poorer outcomes.


Subject(s)
Diabetes Mellitus, Type 1/surgery , Islets of Langerhans Transplantation/immunology , Sirolimus/therapeutic use , Tacrolimus/therapeutic use , Creatinine/metabolism , Diabetes Mellitus, Type 1/drug therapy , Drug Therapy, Combination , Follow-Up Studies , Humans , Hypoglycemic Agents/therapeutic use , Immunosuppressive Agents/therapeutic use , Insulin/therapeutic use , Islets of Langerhans Transplantation/methods , Islets of Langerhans Transplantation/physiology , Kidney Function Tests , Treatment Outcome
12.
Transplant Proc ; 36(2): 316-8, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15050144

ABSTRACT

Two 13-year-old monozygotic twins were used for living related small bowel transplantation (SBTx). The recipient presented with short gut syndrome secondary to complicated abdominal surgery. The indication for SBTx was based on a failure to thrive and a poor tolerance of TPN. The donor was an identical twin, as demonstrated by skin graft acceptance, which allowed performance of SBTx without immunosuppression. Growth charts were used to follow intestinal absorption functions and body composition. The donor was used as a control for the recipient. The recipient, who was transplanted with 160 cm of donor ileum, was discharged on postoperative day 62 on a regular diet. Before SBTx the recipient was 10 kg lighter in body weight than the donor, a gap that was progressively reduced over the follow-up period. A height deficit of 3 cm reversed within 1 year after SBTx. A 10-kg deficit in fat-free body mass was completely extinguished within 18 months. By 18 months posttransplant, recipient serum albumin and prealbumin were normal and comparable to donor values. d-Xylose absorption in the recipient remained lower than that in the donor. Within 6 months fecal fat excretion normalized in the recipient. d-Xylose absorption and fecal fat excretion were always within a normal range in the donor.


Subject(s)
Intestine, Small/transplantation , Adolescent , Body Composition , Failure to Thrive/surgery , Growth , Humans , Infant, Newborn , Intestinal Absorption , Living Donors , Male , Skin Transplantation , Time Factors , Treatment Outcome , Twins, Monozygotic
13.
Transplant Proc ; 36(2 Suppl): 362S-366S, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15041369

ABSTRACT

Protocols for islet transplantation have to take into account the diabetogenicity/islet toxicity of the immunosuppressive agents, namely corticosteroids and calcineurin inhibitors, most notably tacrolimus. The development by the Edmonton group of a sirolimus-based, steroid-free, low-tacrolimus regimen was a significant breakthrough that allowed the rate of insulin independence after islet transplantation to increase from 13% to 80% at 1 year. Drawbacks include the side effects of sirolimus and the reduction in insulin independence to 50% at 3 years, the latter being attributed to prolonged tacrolimus exposure. Currently explored alternatives to tacrolimus include cyclosporine, mycophenolate mofetil, and the novel agent FTY 720. Perspectives for the near future involve the achievement of "prope tolerance" by strategies using lymphocyte-depleting antibodies (anti-thymocyte globulin, campath-1H, hOKT3gamma1 [ala,ala]), or costimulatory blockade (anti-CD154 mAbs, CTLA4-Ig).


Subject(s)
Islets of Langerhans Transplantation/immunology , Cyclosporine/therapeutic use , Drug Therapy, Combination , Humans , Immunosuppression Therapy/adverse effects , Immunosuppression Therapy/methods , Immunosuppressive Agents/therapeutic use , Islets of Langerhans Transplantation/pathology , Lymphocyte Depletion , Sirolimus/therapeutic use
14.
Swiss Surg ; 9(5): 227-36, 2003.
Article in English | MEDLINE | ID: mdl-14601326

ABSTRACT

Living donor liver transplantation is a relatively new procedure in which the right side of the liver is harvested in a healthy donor and transplanted into a recipient. After the first case in 1994, over 3000 cases have been done worldwide. This review summarizes the reasons why the procedure is needed, describes its main technical aspects, highlights the boundaries in which it can be done safely, summarizes the current experience worldwide and describes the main points of the program in our unit. We argue that living-donor transplantation is a viable alternative to a long time on the waiting list for several patients, and it can be performed safely and successfully provided that all precautions are undertaken to minimize the risks in the donor and to increase the chances of a good outcome in the recipients. If these prerequisites are met, and within the framework of a structured multidisciplinary program, we believe that living-donor liver transplantation should be funded by health insurances as a recognized therapeutic option.


Subject(s)
Carcinoma, Hepatocellular/surgery , Hepatectomy/trends , Liver Failure/surgery , Liver Neoplasms/surgery , Liver Transplantation/trends , Living Donors/supply & distribution , Tissue and Organ Harvesting/trends , Adult , Carcinoma, Hepatocellular/mortality , Female , Forecasting , Health Services Needs and Demand/trends , Hepatectomy/mortality , Humans , Liver Failure/mortality , Liver Neoplasms/mortality , Liver Transplantation/mortality , Male , Middle Aged , Survival Rate/trends , Switzerland , Tissue and Organ Harvesting/mortality , Waiting Lists
15.
Swiss Surg ; 9(5): 242-6, 2003.
Article in English | MEDLINE | ID: mdl-14601328

ABSTRACT

Islet of Langerhans transplantation is gaining recognition as a therapy for type 1 diabetes. The procedure involves enzymatic digestion of the pancreatic tissue, purification of the islets from the exocrine tissue, infusion of the islets into the portal vein and implantation in the liver. Until 1999, and overall rate of insulin independence of 14% at one year was reported in the International Islet Transplant Registry. The results of the "Edmonton protocol" since 2000 were a breakthrough in the field, with reports of 80% insulin independence at 1-year after solitary islet transplantation in non uremic patients with brittle type 1 diabetes. A rapamycin-based, steroid-free, islet-sparing immunosuppressive regimen was designed and the problem of the insufficient islet mass was tackled by sequential infusions of islets isolated from at least two pancreatic. The University of Geneva has been involved in clinical islet transplantation since 1992, and has performed 51 allogeneic and 17 autologous. Twenty-one patients have been transplanted in Geneva since 2002. They were five solitary islet transplants, 14 islet after kidney transplants and two simultaneous islet-kidney (SIK) recipients. Insulin independence was achieved in 67%.


Subject(s)
Diabetes Mellitus, Type 1/surgery , Islets of Langerhans Transplantation/methods , Diabetes Mellitus, Type 1/mortality , Drug Therapy, Combination , Follow-Up Studies , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Insulin/metabolism , Insulin Secretion , Kidney Transplantation/methods , Sirolimus/adverse effects , Sirolimus/therapeutic use , Switzerland , Tissue and Organ Harvesting/methods , Transplantation, Heterotopic/methods
16.
Swiss Surg ; 9(5): 237-41, 2003.
Article in English | MEDLINE | ID: mdl-14601327

ABSTRACT

Liver transplantation is a standardized therapy for end-stage liver disease. With current immunosuppressive protocols and patient care, ten-year patient survival rate has reached 60%. Several medical complications may develop during this period, including renal dysfunction, hypertension, diabetes mellitus, hyperlipidemia, and metabolic bone disease. The aim of this article is to analyze long-term results of several clinical trials reporting common medical dysfunctions after liver transplantation and to discuss their management.


Subject(s)
Liver Failure/surgery , Liver Transplantation , Postoperative Complications/etiology , Survivors , Cause of Death , Clinical Trials as Topic , Follow-Up Studies , Humans , Liver Failure/mortality , Liver Transplantation/mortality , Postoperative Complications/mortality , Postoperative Complications/therapy , Survival Analysis , Switzerland
SELECTION OF CITATIONS
SEARCH DETAIL
...